Small CDMO
Market Cap
₹28,517 ₹28,517 Cr.
P/E
0.00
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- The thesis turns live if CDMO order inflows recover sustainably and the large customer's destocking does not recur, alongside timely ex-US Sevoflurane approvals.- The bull path requires faster CDMO commercial conversion and ROW approvals, with utilization and mix driving operating leverage.
- The bear path is driven by renewed destocking or weak biotech funding, delayed approvals, and persistent pricing or consumer-healthcare pressure.

Overview

Shareholder Break-up

Trend

  • 1y
  • 2y
  • 4y
  • 5y
  • 10y
  • Promoter
  • Mutual Funds
  • Insurance Companies
  • FII
  • DII-Others
  • Individual < 2 lac
  • Shares Pledged by Promoters(As a % of Total Promoter Holding)
  • Others

Detailed

FAQs on Piramal Pharma Ltd. Shareholdings

The mutual fund holding of Piramal Pharma is decreasing.
The current mutual fund holding in Piramal Pharma is 13.18% while previous quarter holding is 14.12%.

Promoters seem not to be bullish about the company and have been selling shares in the open market.
Latest quarter promoter holding in Piramal Pharma is 34.8% and last quarter promoter holding is 34.86%

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech